Zürcher Kathrin, Mooser Anne, Anderegg Nanina, Tymejczyk Olga, Couvillon Margaret J, Nash Denis, Egger Matthias
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.
Trop Med Int Health. 2017 Apr;22(4):375-387. doi: 10.1111/tmi.12843. Epub 2017 Feb 20.
The retention of patients on antiretroviral therapy (ART) is key to achieving global targets in response to the HIV epidemic. Loss to follow-up (LTFU) can be substantial, with unknown outcomes for patients lost to ART programmes. We examined changes in outcomes of patients LTFU over calendar time, assessed associations with other study and programme characteristics and investigated the relative success of different tracing methods.
We performed a systematic review and logistic random-effects meta-regression analysis of studies that traced adults or children who started ART and were LTFU in sub-Saharan African treatment programmes. The primary outcome was mortality, and secondary outcomes were undocumented transfer to another programme, treatment interruption and the success of tracing attempts.
We included 32 eligible studies from 12 countries in sub-Saharan Africa: 20 365 patients LTFU were traced, and 15 708 patients (77.1%) were found. Compared to telephone calls, tracing that included home visits increased the probability of success: the adjusted odds ratio (aOR) was 9.35 (95% confidence interval [CI] 1.85-47.31). The risk of death declined over calendar time (aOR per 1-year increase 0.86, 95% CI 0.78-0.95), whereas undocumented transfers (aOR 1.13, 95% CI 0.96-1.34) and treatment interruptions (aOR 1.31, 95% CI 1.18-1.45) tended to increase. Mortality was lower in urban than in rural areas (aOR 0.59, 95% CI 0.36-0.98), but there was no difference in mortality between adults and children. The CD4 cell count at the start of ART increased over time.
Mortality among HIV-positive patients who started ART in sub-Saharan Africa, were lost to programmes and were successfully traced has declined substantially during the scale-up of ART, probably driven by less severe immunodeficiency at the start of therapy.
让患者坚持接受抗逆转录病毒治疗(ART)是实现应对艾滋病毒流行全球目标的关键。失访情况可能很严重,接受ART治疗项目的患者失访后的结局不明。我们研究了随日历时间推移失访患者结局的变化,评估了与其他研究及项目特征的关联,并调查了不同追踪方法的相对成功率。
我们对撒哈拉以南非洲治疗项目中追踪开始接受ART治疗且失访的成人或儿童的研究进行了系统综述和逻辑随机效应元回归分析。主要结局是死亡率,次要结局是未经记录的转至另一项目、治疗中断以及追踪尝试的成功率。
我们纳入了撒哈拉以南非洲12个国家的32项符合条件的研究:对20365名失访患者进行了追踪,找到了15708名患者(77.1%)。与电话追踪相比,包含家访的追踪增加了成功的可能性:调整后的优势比(aOR)为9.35(95%置信区间[CI]1.85 - 47.31)。死亡风险随日历时间下降(每增加1年aOR为0.86,95%CI 0.78 - 0.95),而未经记录的转至另一项目(aOR 1.13,95%CI
0.96 - 1.34)和治疗中断(aOR 1.31,95%CI 1.18 - 1.45)则趋于增加。城市地区的死亡率低于农村地区(aOR 0.59,95%CI 0.36 - 0.98),但成人和儿童的死亡率没有差异。ART开始时的CD4细胞计数随时间增加。
在撒哈拉以南非洲开始接受ART治疗、失访且成功追踪的艾滋病毒阳性患者中,死亡率在ART扩大规模期间大幅下降,这可能是由于治疗开始时免疫缺陷程度较轻所致。